Literature DB >> 10993292

Progressive reduction of CMV-specific CD4+ T cells in HIV-1 infected individuals during antiretroviral therapy.

V Grosse1, A Schulte, K Weber, M Mendila, R Jacobs, R E Schmidt, H Heiken.   

Abstract

Visualization of antigen-specific T cells has become an important tool in studying immune responses. The aim of this study was to analyze CMV-specific CD4+ T cells in healthy and HIV-infected individuals. Peripheral blood mononuclear cells (PBMC) were examined for antigen-induced intracellular cytokine responses. We found significant numbers of CMV-specific CD4+ T cells detectable in most CMV-IgG+ HIV-1 infected individuals, whereas CMV-specific CD4+ T cells could not be demonstrated in CMV-IgG- patients. Median frequency of CMV-specific CD4+ T cells were lower in HIV-infected subjects who had been treated with highly active antiretroviral therapy (HAART) for more than 1 year than in untreated HIV-infected individuals. In patients under therapy for less than 1 year median CMV-specific CD4+ T cell responder frequency was higher than in subjects treated for more than 1 year but lower than in untreated subjects. HIV suppression with HAART might lead to a progressive reduction of CMV-specific CD4+ T cells indicating an efficient elimination of an opportunistic pathogen.

Entities:  

Mesh:

Year:  2000        PMID: 10993292     DOI: 10.1016/S0171-2985(00)80064-9

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  2 in total

Review 1.  Enteric viruses in HIV-related diarrhoea.

Authors:  R C Pollok; M J Farthing
Journal:  Mol Med Today       Date:  2000-12

2.  Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.

Authors:  Denise C Hsu; Stephen J Kerr; Thatri Iampornsin; Sarah L Pett; Anchalee Avihingsanon; Parawee Thongpaeng; John J Zaunders; Sasiwimol Ubolyam; Jintanat Ananworanich; Anthony D Kelleher; David A Cooper
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.